Fundraising Fox

Aegle Therapeutics

Woburn, US · Delaware corporation · 3 known investors

aegletherapeutics.com ↗

Aegle Therapeutics develops therapies using extracellular vesicles (EVs) isolated from mesenchymal stem cells to deliver therapeutic biomolecules to diseased and damaged cells. Its lead product, AGLE-102, targets dystrophic epidermolysis bullosa, a rare pediatric skin-blistering disease, with potential applications across dermatology, immunology, and protein-deficiency disorders.

BiotechHealthtechMedical Devices

Founders & leadership

EB
Evangelos BadiavasDirector
SH
Shelley HartmanExecutive Officer, Director
RW
Robert Williamson, Jr.Executive Officer, Director
RR
Robert RyanDirector
LM
Leon Moulder, Jr.Director
SA
Shelley A. HartmanCo-founder & CEO
EV
Evangelos V. BadiavasFounder & Chief Scientific Officer
HK
Heidi KempinskiChief Operational Officer
KM
Kathleen MurphyHead of Clinical Operations
MT
Mikio TanjiDirector
EB
Elona BaumDirector
DS
David SchimelDirector

Investors · 3

DEFTA PartnersSan Francisco
New World AngelsBoca Raton
Ocean Azul PartnersCoral Gables · $500K – $2M

Reported raises · per SEC filings

Form D private placements
▶$455.7KraisedMar 2026 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Evangelos BadiavasDirector
  • Shelley HartmanExecutive Officer, Director
  • David SchimelDirector
  • Scott BraunsteinDirector
  • Leon MoulderDirector
  • Mikio TanjiDirector
  • Steve O'HaraDirector
Offering amount
$700K
Amount sold
$455.7K
First sale
Dec 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.5MraisedJul 2020 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Shelley HartmanExecutive Officer, Director
  • Evangelos BadiavasExecutive Officer, Director
  • Robert Williamson, Jr.Executive Officer, Director
  • David SchimelDirector
  • Robert RyanDirector
  • Elona BaumDirector
  • Leon Moulder, Jr.Director
Offering amount
$6.5M
Amount sold
$6.5M
First sale
Jan 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.